I read Dr. Robert L. Barbieri’s editorial, “The pipeline runneth over” (January), with great interest. It’s nice to see some attention paid to drugs likely to be of use to gynecologists. I share Dr. Barbieri’s enthusiasm for this area of research.
Like Dr. Barbieri, I am concerned about the lack of development in the obstetric arena, with one glaring exception: Columbia Labs’ (Livingston, NJ) ongoing study of the vaginal progesterone gel, Prochieve, for the new indication of preventing preterm delivery. If the gel proves to be effective in the trial, it will be an important advance.
Ken Muse, MD
Associate Professor and Director
Division of Reproductive Endocrinology
Department of Obstetrics and Gynecology
University of Kentucky Medical Center, Lexington
Dr. Muse has received grant/research support from and is a speaker for Columbia Labs.